Control of refractory hypercalcemia with denosumab in a case of metastatic parathyroid carcinoma
dc.contributor.author | Çalapkulu, Murat | |
dc.contributor.buuauthor | Gül, Özen Öz | |
dc.contributor.buuauthor | Cander, Soner | |
dc.contributor.buuauthor | Ersoy, Canan Özyardımcı | |
dc.contributor.buuauthor | Ertürk, Erdinç | |
dc.contributor.buuauthor | Sağıroğlu, Muhammed Fatih | |
dc.contributor.buuauthor | Saraydaroğlu, Özlem | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı. | tr_TR |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı. | tr_TR |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | AAJ-6536-2021 | |
dc.contributor.researcherid | AAH-8861-2021 | |
dc.contributor.researcherid | AAH-9701-2021 | |
dc.contributor.researcherid | AAI-1005-2021 | |
dc.contributor.researcherid | CJH-1319-2022 | |
dc.contributor.researcherid | DPC-0292-2022 | |
dc.contributor.scopusid | 26040787100 | tr_TR |
dc.contributor.scopusid | 25027068600 | tr_TR |
dc.contributor.scopusid | 6701485882 | tr_TR |
dc.contributor.scopusid | 7005488796 | tr_TR |
dc.contributor.scopusid | 57218578082 | tr_TR |
dc.contributor.scopusid | 15074395500 | tr_TR |
dc.date.accessioned | 2024-01-31T06:08:04Z | |
dc.date.available | 2024-01-31T06:08:04Z | |
dc.date.issued | 2019-07-21 | |
dc.description.abstract | Parathyroid carcinoma is a rare cause of hyperparathyroidism and leads to severe hypercalcemia. The etiology is not fully known. Parathyroid cancer should be considered in the differential diagnosis, if serum calcium and parathyroid hormone levels increase, and parathyroid gland is palpable. Severe hypercalcemia is the most common cause of death in patients diagnosed with parathyroid carcinoma. Fluid replacement, diuretic therapy, bisphosphonates, and calcimimetic agents are the main treatment steps in the control of life-threatening hypercalcemia. Surgery is the primary treatment option, while denosumab is a treatment option for refractory hypercalcemia caused by parathyroid carcinoma, or for patients who are not eligible for surgery. There are few case reports in literature about denosumab treatment for parathyroid carcinoma. Herein, we report a case of a patient who presented with the complaint of leg pain and was diagnosed with parathyroid carcinoma. The elevated calcium level of the patient was controlled with denosumab. | en_US |
dc.identifier.citation | Çalapkulu, M. vd. (2020). ''Control of refractory hypercalcemia with denosumab in a case of metastatic parathyroid carcinoma''. JCPSP-Journal of the College of Physicians and Surgeons Pakistan, 30(7), 757-759. | en_US |
dc.identifier.doi | https://doi.org/10.29271/jcpsp.2020.07.757 | |
dc.identifier.eissn | 1681-7168 | |
dc.identifier.endpage | 759 | tr_TR |
dc.identifier.issn | 1022-386X | |
dc.identifier.issue | 7 | tr_TR |
dc.identifier.pubmed | 32811610 | tr_TR |
dc.identifier.scopus | 2-s2.0-85089640645 | tr_TR |
dc.identifier.startpage | 757 | tr_TR |
dc.identifier.uri | https://jcpsp.pk/article-detail/control-of-refractory-hypercalcemia-with-denosumab-in-a-case-of-metastatic-parathyroid-carcinoma | |
dc.identifier.uri | https://hdl.handle.net/11452/39402 | |
dc.identifier.volume | 30 | tr_TR |
dc.identifier.wos | 000561256500026 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | College of Physicians and Surgeons Pakistan | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.journal | JCPSP-Journal of the College of Physicians and Surgeons Pakistan | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Parathyroid carcinoma | en_US |
dc.subject | Denosumab | en_US |
dc.subject | Hypercalcemia | en_US |
dc.subject | Hyperparathyroidism | en_US |
dc.subject | Management | en_US |
dc.subject | General & internal medicine | en_US |
dc.subject.emtree | Alkaline phosphatase | en_US |
dc.subject.emtree | Calcium | en_US |
dc.subject.emtree | Cinacalcet | en_US |
dc.subject.emtree | Creatinine | en_US |
dc.subject.emtree | Denosumab | en_US |
dc.subject.emtree | Furosemide | en_US |
dc.subject.emtree | Parathyroid hormone | en_US |
dc.subject.emtree | Phosphorus | en_US |
dc.subject.emtree | Zoledronic acid | en_US |
dc.subject.emtree | Bisphosphonic acid derivative | en_US |
dc.subject.emtree | Bone density conservation agent | en_US |
dc.subject.emtree | Denosumab | en_US |
dc.subject.emtree | Parathyroid hormone | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Alkaline phosphatase blood level | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Bone metastasis | en_US |
dc.subject.emtree | Bone scintiscanning | en_US |
dc.subject.emtree | Calcium blood level | en_US |
dc.subject.emtree | Cancer recurrence | en_US |
dc.subject.emtree | Case report | en_US |
dc.subject.emtree | Cervical spine radiography | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Continuous infusion | en_US |
dc.subject.emtree | Creatinine blood level | en_US |
dc.subject.emtree | Echography | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Histopathology | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Hypercalcemia | en_US |
dc.subject.emtree | Leg pain | en_US |
dc.subject.emtree | Lymphadenopathy | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Nuclear magnetic resonance imaging | en_US |
dc.subject.emtree | Parathyroid cancer | en_US |
dc.subject.emtree | Parathyroid carcinoma | en_US |
dc.subject.emtree | Parathyroid hormone blood level | en_US |
dc.subject.emtree | Parathyroid scintiscanning | en_US |
dc.subject.emtree | Parathyroidectomy | en_US |
dc.subject.emtree | Phosphate blood level | en_US |
dc.subject.emtree | Postoperative period | en_US |
dc.subject.emtree | Spine radiography | en_US |
dc.subject.emtree | Thorax radiography | en_US |
dc.subject.emtree | Treatment duration | en_US |
dc.subject.emtree | Treatment response | en_US |
dc.subject.emtree | Complication | en_US |
dc.subject.emtree | Hypercalcemia | en_US |
dc.subject.emtree | Parathyroid tumor | en_US |
dc.subject.mesh | Bone density conservation agents | en_US |
dc.subject.mesh | Denosumab | en_US |
dc.subject.mesh | Diphosphonates | en_US |
dc.subject.mesh | Parathyroid hormone | en_US |
dc.subject.mesh | Parathyroid neoplasms | en_US |
dc.subject.mesh | Hypercalcemia | en_US |
dc.subject.scopus | Cancer; Primary Hyperparathyroidism; Denosumab | en_US |
dc.subject.wos | Medicine, general & internal | en_US |
dc.title | Control of refractory hypercalcemia with denosumab in a case of metastatic parathyroid carcinoma | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q4 (Medicine, general & internal) | en_US |